DA
FOLD

Duality Advisers’s Amicus Therapeutics FOLD Stock Holding History

Duality Advisers’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-37,555
Closed -$442K – 201
2024
Q1 		$442K Buy
37,555
+10,792
+40% +$138K 0.04% 461
2023
Q4 		$380K Buy
26,763
+9,619
+56% +$109K 0.04% 469
2023
Q3 		$208K Buy
+17,144
New +$221K 0.03% 520
2023
Q2 		– Sell
-94,890
Closed -$1.05M – 585
2023
Q1 		$1.05M Buy
94,890
+16,833
+22% +$207K 0.12% 294
2022
Q4 		$953K Sell
78,057
-106,530
-58% -$1.2M 0.11% 325
2022
Q3 		$1.93M Buy
+184,587
New +$2.06M 0.21% 187

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Duality Advisers's FOLD Position: Q2 2024 in Review

Duality Advisers sold out of Amicus Therapeutics (FOLD) in Q2 2024, closing a stake of 37,555 shares — an estimated $442K sold.

Duality Advisers first reported a position in FOLD in Q3 2022 and held it in 6 quarters. The position peaked at $1.93M in Q3 2022. 258 funds tracked by Wall St. Rank hold FOLD as of Q2 2024.

  • Duality Advisers reported no remaining Amicus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Duality Advisers sold 37,555 Amicus Therapeutics shares in Q2 2024, an estimated $442K.
  • Duality Advisers first reported a position in Amicus Therapeutics in Q3 2022 and held it in 6 quarters.
  • Duality Advisers's Amicus Therapeutics position peaked at $1.93M in Q3 2022.
  • 258 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2024.

Based on Duality Advisers's 13F filing for Q2 2024.